bromocriptine

(redirected from Cycloset)
Also found in: Dictionary, Encyclopedia.
Related to Cycloset: bromocriptine

bromocriptine

 [bro″mo-krip´tēn]
an ergot alkaloid that acts as a dopamine agonist; used as the mesylate salt to suppress prolactin secretion in the treatment of pituitary prolactinomas and of hyperprolactinemia-associated amenorrhea, galactorrhea, infertility, or male hypogonadism. It is also used as an antidyskinetic, usually in conjunction with levodopa, in the treatment of parkinsonism, and is used as a growth hormone suppressant in the treatment of acromegaly. Administered orally.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

bromocriptine

(brō′mō-krĭp′tēn)
n.
An ergot alkaloid, C32H40BrN5O5, that is a dopamine antagonist and is used in its mesylate form to treat Parkinson's disease, acromegaly, and excessive prolactin secretion, and to reduce the size of certain pituitary tumors.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.

bromocriptine

Endocrinology
An ergoline derivative which reduces pituitary prolactin secretion and size of pituitary tumours.
 
Indications
Hyperprolactinemia, pituitary tumours, amenorrhoea, female infertility, hypogonadism, acromegaly, Parkinson’s disease, neuroleptic malignant syndrome, type-2 diabetes.
 
Adverse effects
Orthostatic hypotension, vomiting, vertigo, headaches, upset stomach, coronary vasospasm, pulmonary fibrosis, hepatotoxicity.

Immunology
A dopamine D2-receptor inhibitor which inhibits T-cell-dependent induction of macrophage tumouricidal activity.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

bromocriptine

An ERGOT derivative drug with DOPAMINE-like effects. It is used in the treatment of PARKINSON'S DISEASE and ACROMEGALY and given to prevent LACTATION by inhibiting the secretion of the hormone prolactin by the pituitary gland. A brand name is Parlodel.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005

Bromocriptine

Also known as Parlodel, the main drug used to treat galactorrhea by reducing levels of the hormone prolactin.
Mentioned in: Galactorrhea, Lactation
Gale Encyclopedia of Medicine. Copyright 2008 The Gale Group, Inc. All rights reserved.
References in periodicals archive ?
Cycloset is the first drug to win FDA approval under new guidelines that require better evidence that diabetes treatments are heart-safe.
People don't have those seasonal variations but the theory is the dopamine plays a role anyway in sensitivity to insulin, although Cycloset apparently did not affect weight.
CYCLOSET is a prescription drug approved by the US Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus both as monotherapy and in combination with other oral antidiabetic agents.
A 24-week, placebo-controlled, monotherapy study of the impact of CYCLOSET on glycemic control in 159 overweight adults with Type 2 diabetes and baseline HbA1c of 7.5%-11% indicated that once-daily morning dosing of CYCLOSET provided significant postprandial plasma glucose reductions throughout the day without increasing plasma insulin concentrations and significantly improved HbA1c.
Additional data from a prospective 24-week assessment of the efficacy of CYCLOSET in improving glycemic control in Type 2 diabetes, patients poorly controlled on one or two oral anti-diabetes agents indicated that 35% - 40% of patients reached an HbA1c goal of equal or lower than 7% with CYCLOSET versus approximately 10% of placebo treated patients.
<p>Speciality biopharmaceutical company Santarus Inc (NASDAQ:SNTS) reported on Wednesday the execution of a distribution and licence agreement to acquire the exclusive rights to manufacture and commercialise CYCLOSET (bromocriptine mesylate) tablets in the US for type 2 diabetes.</p><p>This agreement was signed with S2 Therapeutics Inc and VeroScience LLC.</p><p>Pursuant to the agreement Santarus will pay an upfront fee of USD5m to S2 Therapeutics and VeroScience.
CYCLOSET improves glycemic control without increasing cardiovascular event risk.
Charles Sutphin, co-chairman, president and chief executive officer of S2 Therapeutics said, that the company is excited about the distribution and license agreement with Santarus for CYCLOSET and the strategic fit with its organisation.
Cycloset is taken by mouth once daily in the morning, and results in a "brief pulse of dopamine agonist activity shortly after its administration," which improves postprandial glucose without increasing plasma insulin concentrations, according to a statement issued by VeroScience.
Bromocriptine is a sympatholytic dopamine D2 receptor agonist that can "exert inhibitor effects on serotonin in the central nervous system," according to a ClinicalTrials.gov summary of a phase III study of Cycloset.